# Legend Biotech Corporation (LEGN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/LEGN
## Company Profile
- Ticker: LEGN
- Exchange: NASDAQ
- Sector: CAR-T Therapy, TCR-T Therapy, Antibody Drugs, ADCs, Biopharma
- Location: China with major global operations and listed in the U
- Tags: TCR-T Therapy, CAR-T Therapy, Antibody Drugs, ADCs, Oncology
## Stock Data
- Close: 20.65 USD
- Market cap: 6738639653.76 USD
- Last updated: 2026-08-12
## Business Overview
### Global Cell Therapy Company
Legend Biotech develops and commercializes cell therapies for cancer and other serious diseases.
### CARVYKTI
CARVYKTI, or ciltacabtagene autoleucel, is a one-time BCMA-directed CAR T-cell therapy for multiple myeloma developed and commercialized with Johnson & Johnson.
### Global Manufacturing and Access
Legend supports CARVYKTI across 18 markets through expanding manufacturing capacity, treatment-center certification, and partner-led commercialization.
### CARVYKTI Clinical Expansion
The cilta-cel franchise is being developed across earlier lines of multiple myeloma treatment to broaden access beyond heavily pretreated disease.
### Earlier Cell Therapy Pipeline
The company is advancing additional cell therapies beyond BCMA, including programs for hematologic malignancies and solid tumors.
## Why The Stock Is Moving

Following the latest company update, “Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights”, LEGN closed up 5.66% at $21.83 on Aug 11, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Legend Biotech’s catalysts are Carvykti sales growth, label-expansion opportunities, and further commercial execution in multiple myeloma. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.

## Recent News
- 2026-08-11 11:00 EST — [Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights](https://biopharmsignal.com/news/LEGN/legend-biotech-reports-second-quarter-2026-results-and-recent-highlights-e2e82cac) — Source: Legend Biotech Corporation
- 2026-07-28 12:00 EST — [Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results](https://biopharmsignal.com/news/LEGN/legend-biotech-to-host-investor-conference-call-on-second-quarter-2026-results-3744bba0) — Source: Legend Biotech Corporation
- 2026-07-27 10:00 EST — [Legend Biotech Announces CEO Transition](https://biopharmsignal.com/news/LEGN/legend-biotech-announces-ceo-transition-6f26346e) — Source: Legend Biotech Corporation
- 2026-06-18 01:21 EST — [Legend Biotech Corporation Announces Pricing of Public Offering](https://biopharmsignal.com/news/LEGN/legend-biotech-corporation-announces-pricing-of-public-offering-c0ab1d0b) — Source: Legend Biotech Corporation
- 2026-06-17 20:29 EST — [Legend Biotech Corporation Announces Proposed Public Offering](https://biopharmsignal.com/news/LEGN/legend-biotech-corporation-announces-proposed-public-offering-3615b70e) — Source: Legend Biotech Corporation